Empowering the ECG
for new clinical applications

Our research and pipeline recognize the potential of ECGs beyond their traditional boundaries and towards the detection and management of:

Structural Heart Conditions
Cardiomyopathies
Heart Failure
Electrolyte Dysfunctions

AK+ Guard: Remote Monitoring for Hyperkalemia

Extending the Lab to the Home

AK-AVS: ECG Based Screening for Aortic Stenosis

A New Paradigm in Detection and Monitoring for AS

ECG can be deployed for the widespread screening of
aortic stenosis

Earlier detection and treatment will lead to better outcomes and lower costs

Underdiagnosis of aortic stenosis is a major problem

A new approach is needed to improve detection

High mortality for aortic stenosis

As high as 50% in one year¹

Delayed treatment increases costs

$10k additional cost per patient per year²

High rate of aortic stenosis underdiagnosis

Up to 50% of AS cases are missed until post-mortem³

There is a new approach to addressing underdiagnosis

AccurKardia proposes to improve timely diagnosis through systematic ECG-based screening

Unique benefits of AccurKardia's
ECG-based screening approach

AK-AVS receives

FDA Breakthrough Device Designation

Rapidly process massive amounts of preexisting ECGs

Concentrated deployment at the EHR system level

No disruption to point of care workflow

No new devices / equipment

Facilitate clinical trial enrollment for moderate and asymptomatic AS

AK-AVS Performance*

74%

Sensitivity

86%

Specificity

83%

Accuracy

Download our White Paper: AK-AVS - A New Paradigm in Aortic Stenosis Detection

Gain in-depth insights into how AccurKardia’s AI-powered AK-AVS technology enhances early detection of aortic stenosis through ECG screening.

*Detection of moderate and severe aortic stenosis clinical validation based on data from Mayo Clinic Platform_Accelerate Cohort 3 Dataset from Mayo Clinic.

Remote Monitoring for Hyperkalemia:
Extending the Lab to the Home

AK+ Guard™ can process Lead I ECG data from wearables to remotely monitor hyperkalemia in at-risk patients.

Hyperkalemia Risk

A potentially fatal condition that can lead to sudden cardiac arrest, hyperkalemia is associated with a 16.6% increase in all-cause mortality in chronic kidney disease (CKD) patients.⁴

Importance of Monitoring

Because hyperkalemia is often asymptomatic or presents non-specific symptoms, continuous monitoring is critical for high-risk patients.

Pronounced Risk in Dialysis Patients

The all-cause mortality rate after a moderate to severe hyperkalemia episode (>6.0 mEq/L) is 33% and the annual prevalence is 17%.⁵^,⁶

Remote Intervention

Remote monitoring enables timely alerts for patients and providers, prompting earlier intervention to prevent exacerbations or sudden cardiac events.

AK+ Guard Hyperkalemia Model Performance*

81.2%

Sensitivity

83.2%

Specificity

89.0%

Accuracy

*Detection of moderate to severe hyperkalemia episodes based clinical validation on data from Mayo Clinic Platform_Accelerate Cohort 3 Dataset, from Mayo Clinic.

ECG can be a powerful biomarker for cardiology and beyond

AccurKardia’s ECG-based tests compare favorably to widely used diagnostics

PSA for Prostate Cancer⁷

Hemoglobin A1C for Diabetes⁸

Cornell Voltage for LVH⁹

Coronary calcium Scoring CT¹⁰

Spirometry for COPD¹¹

Tonometry for Glaucoma¹²

AK-AVS^TM

AK+ Guard^TM

AK-AVS = Moderate-to-Severe Aortic Valve Stenosis Detection Model

AK+ Guard = Moderate-to-Severe Hyperkalemia Detection Model

Future Pipeline

Electrolyte Dysfunctions

Amyloidosis

Heart Failure

Bevan, G. (2019). Mortality Due to Aortic Stenosis in the United States, 2008-2017. JAMA, 2236-2238.
Sethi, A, MD (2024). The Cost of Waiting for a Transcatheter Aortic Valve Replacement in Medicare Beneficiaries With Severe Aortic Stenosis. Structural Heart.
Das, P. (2000). The patient with a systolic murmur: severe aortic stenosis may be missed during cardiovascular examination. QJM, 685–688.
Collins, A. J., Pitt, B., Reaven, N., Funk, S., McGaughey, K., Wilson, D., & Bushinsky, D. A. (2017).Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and/or diabetes. American Journal of Nephrology, 46(3), 213–221.
Karaboyas, A., Robinson, B., James, G., Hedman, K., Quinn, C. P. M., De Sequera, P., ... & Pecoits-Filho, R. (2021).Hyperkalemia excursions are associated with an increased risk of mortality and hospitalizations in hemodialysis patients. Clinical Kidney Journal, 14(7), 1760–1769.
Agiro, A., Duling, I., Eudicone, J., Davis, J., Brahmbhatt, Y. G., & Cooper, K. (2022).The prevalence of predialysis hyperkalemia and associated characteristics among hemodialysis patients: The RE-UTILIZE study. Hemodialysis International, 26(3), 285–458.
Lee, R. (2006). A meta-analysis of the performance characteristics of the free prostate-specific antigen test. Urology, 762-768.
Lee, T. (2006). A1C Testing in the Diagnosis of Diabetes Mellitus. American Family Physician, 143-144.
Noubiap, J. (2020). A meta‐analytic evaluation of the diagnostic accuracy of the electrocardiographic Peguero‐Lo Presti criterion for left ventricular hypertrophy. Journal of Clinical Hypertension, 1145-1153.
Neves, P. (2017). Coronary artery calcium score: current status. Radiologica Brasileira. 182-189.
Johns, P. (2014). Diagnosis and early detection of COPD using spirometry. Journals of Thoracic Disease. 1557-1569.
Chou, R. (2022). Screening for Glaucoma in Adults, JAMA Network. 1998-2012

The AK-AVS™ and AK+ Guard™ are registered trademarks of AccurKardia, Inc., with all intellectual property rights owned by AccurKardia, Inc.

AK-AVS™ and AK+ Guard™ are currently for research use only and have not been cleared or approved by the US FDA for use in the United States. This technology is under development and intended solely for investigational purposes. It should not be used for clinical diagnosis, treatment, or disease screening at this time. AK-AVS™ and AK+ Guard™ are currently patent pending.

The information provided on this website is for informational purposes only and does not constitute medical, legal, or professional advice. Always consult a qualified healthcare provider for clinical decision-making.

Empowering the ECG for new clinical applications